Journal
XENOBIOTICA
Volume 46, Issue 2, Pages 147-162Publisher
TAYLOR & FRANCIS LTD
DOI: 10.3109/00498254.2015.1060372
Keywords
HIV-1; integrase inhibitor; long-acting injectable; nanosuspension
Categories
Ask authors/readers for more resources
1.Cabotegravir [(3S,11aR)-N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3]oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide] is an HIV-1 integrase inhibitor under development as a tablet for both oral lead-in therapy and long-acting (LA) injectable for intramuscular dosing.2. Metabolism, pharmacokinetics and excretion were investigated in healthy human subjects who received either a single oral dose (28.2mg) of [C-14]cabotegravir in a mass balance study, or LA formulations of unlabeled cabotegravir (200-800mg), intramuscularly or subcutaneously, in a separate study. Metabolism, distribution and excretion of [C-14]cabotegravir were also investigated in mice, rats and monkeys.3. Recovery of radioactivity in humans represented a mean total of 85.3% of the dose, including 26.8% in the urine. The mean apparent terminal phase half-life was similar for both cabotegravir and radioactivity, 39h compared to 41h.4. Following oral, intramuscular and subcutaneous administration, cabotegravir was the major component in plasma and the glucuronic acid conjugate (M1) represented the predominant component in urine. Cabotegravir was present in bile along with its major metabolite (M1).5. The primary metabolite of [C-14]cabotegravir in mouse, rat and monkey was the same as that in human. In vitro phenotyping experiments demonstrated that cabotegravir was metabolized by UDP-glucuronosyltransferase (UGT) 1A1 and UGT1A9.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available